Chemotherapy Induced Neutropenia (CIN) commonly occurs during current cancer treatments involving cytotoxic chemotherapy. If left untreated, the reduction of these critical immune cells means that patients suffering from CIN are much more vulnerable to other infections. Mortality rates from opportunistic infections due to CIN mean that almost as many patients treated, with chemotherapy succumb to CIN as to the cancer being treated.
Furthermore, concerns around the risk and prognosis of CIN mean that some patients with poor prognosis forgo chemotherapy treatment altogether. Market research indicates that CIN affects more than 8 million people every year with around 1 million people affected in the US alone.
CIN is primarily treated with Granulocyte-Colony Stimulating Factor (G-CSF) and antibiotics. These long-acting G-CSFs also present unmet medical needs as highly heterogeneous populations that respond inconsistently to currently available options, and some sub-populations of patients are unresponsive to current therapies or do not tolerate pegylated products. F-627’s novel dimeric fusion protein structure addresses these unmet medical needs by providing a safe and efficacious alternative to current long-acting G-CSFs that avoids pegylation.
See the results of our Phase III China trials comparing the efficacy and safety of F-627 and GRAN®
See our Phase III Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy